U.S. Markets closed
  • S&P 500

    3,577.59
    +20.05 (+0.56%)
     
  • Dow 30

    29,591.27
    +327.79 (+1.12%)
     
  • Nasdaq

    11,880.63
    +25.66 (+0.22%)
     
  • Russell 2000

    1,818.30
    +32.96 (+1.85%)
     
  • Crude Oil

    42.99
    -0.07 (-0.16%)
     
  • Gold

    1,835.10
    -2.70 (-0.15%)
     
  • Silver

    23.59
    -0.04 (-0.16%)
     
  • EUR/USD

    1.1844
    -0.0018 (-0.1540%)
     
  • 10-Yr Bond

    0.8570
    +0.0280 (+3.38%)
     
  • Vix

    22.66
    -1.04 (-4.39%)
     
  • GBP/USD

    1.3324
    +0.0033 (+0.2492%)
     
  • USD/JPY

    104.5110
    +0.6830 (+0.6578%)
     
  • BTC-USD

    18,296.84
    -157.90 (-0.86%)
     
  • CMC Crypto 200

    365.78
    +4.35 (+1.20%)
     
  • FTSE 100

    6,333.84
    -17.61 (-0.28%)
     
  • Nikkei 225

    25,527.37
    -106.93 (-0.42%)
     

GLNG, GTX & BMRN Reminders: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Lead Plaintiff Deadlines

·3 min read

NEW YORK, NY / ACCESSWIRE / October 28, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Golar LNG Limited (NASDAQ:GLNG)
Class Period:
April 30, 2020 - September 24, 2020
Deadline: November 23, 2020
For more info: www.bgandg.com/glng

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements that: (1) certain employees, including Hygo's CEO, had bribed third parties, thereby violating anti-bribery policies; (2) as a result, the Company was likely to face regulatory scrutiny and possible penalties; (3) as a result of the foregoing reputational harm, Hygo's valuation ahead of its IPO would be significantly impaired; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Garrett Motion Inc. (NYSE:GTX)
Class Period:
October 1, 2018 - September 18, 2020
Deadline: November 24, 2020
For more info: www.bgandg.com/gtx

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements that: (1) due to its agreement to indemnify and reimburse Honeywell for certain asbestos-related liability, Garrett was saddled with an unsustainable level of debt; (2) as a result, Garrett had a highly leveraged capital structure that posed significant challenges to its overall strategic and financial flexibility; (3) as a result of the foregoing, Garrett's ability to gain or hold market share was impaired; (4) as a result of the foregoing, the Company was reasonably likely to seek bankruptcy protection; and (5) consequently, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Class Period:
February 28, 2020 - August 18, 2020
Deadline: November 24, 2020
For more info: www.bgandg.com/bmrn

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements that: (1) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (2) as a result, it was foreseeable that the U.S. Food and Drug Administration ("FDA") would not approve the Biologics License Application ("BLA") for valoctocogene roxaparvovec without additional data; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/612147/GLNG-GTX-BMRN-Reminders-Bronstein-Gewirtz-Grossman-LLC-Reminds-Investors-of-Class-Actions-and-Lead-Plaintiff-Deadlines